Palvella Therapeutics carries an analyst consensus price target implying 97% upside from current levels with an asymmetry ratio of 5.5, but the company has missed earnings estimates in all 4 of the last 4 quarters while burning cash, concentrating its entire pipeline on a single asset (QTORIN rapamycin) in a high-risk binary outcome.
Thesis pillars
- Analyst Upside Conviction↓Deteriorating
- Single Asset Pipeline Concentration↓Deteriorating
- Consistent Earnings Misses↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 31, 2026· older than 90 days
Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $162.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality.
Palvella Therapeutics develops topical therapies for rare skin diseases and vascular malformations using its QTORIN platform, with no approved products or product revenue. Lead candidate QTORIN rapamycin met its Phase 3 primary endpoint for microcystic LMs in February 2026, with... Read more
Sell if holding. Engine safety override at $162.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Palvella Therapeutics, Inc.
About Palvella Therapeutics, Inc.
Palvella Therapeutics reported positive Phase 3 SELVA results for QTORIN rapamycin in microcystic lymphatic malformations in February 2026, with a mean +2.13-point mLM-IGA improvement (p<0.001) across 49 participants aged 6 and older; an NDA submission is planned for 2H 2026. The company had no product revenue, recording a $38.6 million operating loss in 2025 and holding a $135.5 million accumulated deficit as of December 31, 2025.
Palvella has no commercialized products and generates no revenue. The QTORIN platform delivers therapeutics to deep skin layers with minimal systemic absorption by optimizing excipient-to-API ratios; to date it has generated QTORIN rapamycin (targeting microcystic LMs, cutaneous VMs, and clinically significant angiokeratomas) and QTORIN pitavastatin (targeting DSAP), covering four indications. Manufacturing depends on contract manufacturers, and the company flags the risk that any CMO could fail to remain in good standing with relevant regulatory authorities. Financial obligations include milestone payments under the Amended Ligand Agreement of up to $5.0 million in aggregate due prior to any product commercialization. U.S. patents on anhydrous gel rapamycin formulations expire in 2038 and, for certain applications if issued, as late as 2042. The company's $58.0 million cash balance at December 31, 2025 was supplemented by $215.8 million in net proceeds from a completed public offering, which Palvella estimates is sufficient to fund planned operations for at least twelve months from the Annual Report date.
Show full overview
The 10-K explicitly states that Palvella's future success is substantially dependent on the successful clinical development, regulatory approval, and commercialization of QTORIN rapamycin. Prior programs using QTORIN rapamycin — a Phase 2b study in Gorlin Syndrome and a Phase 3 study in pachyonychia congenita — failed to meet their respective primary endpoints, establishing that efficacy is indication-specific rather than platform-universal. The FDA has noted that a placebo-controlled trial or additional trials assessing different endpoints may be required for microcystic LMs, creating approval uncertainty that exists independently of the positive SELVA topline data.
See also: Healthcare · Biotechnology
From Palvella Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Palvella Therapeutics, Inc.
Latest news
- NEWS Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference — fiscal.ai Nov 3, 2026
- NEWS Palvella Therapeutics to Host Third Quarter 2026 Financial Results Conference Call — fiscal.ai Oct 29, 2026 neutral
- NEWS FDA Grants Priority Review to Palvella Therapeutics' NDA for QTORIN™ Rapamycin — fiscal.ai Oct 28, 2026 positive
- NEWS Palvella Therapeutics CEO to Present at Ligand Pharmaceuticals Investor Day — fiscal.ai Oct 22, 2026 neutral
- NEWS William Blair Initiates Coverage of Palvella Therapeutics — fiscal.ai Oct 22, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-05T11:54:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineQTORIN rapamycin10-K Item 1A: 'Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWBoard increased from 6 to 7; John Doux, M.D. appointed as Class III director effective April 13, 2026, with term expiring at the 2026 Annual Meeting. No officer departures.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $162.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $150.92. Score 5.4/10, moderate confidence.
Analyst target: $205.56 (+26.7% upside). Prior stop was $150.92. Stop-loss: $150.92.
Concentration risk — Pipeline: QTORIN rapamycin; Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow.
Palvella Therapeutics, Inc. trades at a P/E of N/A (forward -20.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts rate PVLA, with a consensus score of 4.3/5. 15 analysts publish price targets averaging $228.
What does Palvella Therapeutics, Inc. do?Palvella Therapeutics develops topical therapies for rare skin diseases and vascular malformations using its QTORIN...
Palvella Therapeutics develops topical therapies for rare skin diseases and vascular malformations using its QTORIN platform, with no approved products or product revenue. Lead candidate QTORIN rapamycin met its Phase 3 primary endpoint for microcystic LMs in February 2026, with an NDA planned for 2H 2026. The company had $58.0 million in cash plus $215.8 million from a recent offering as of December 31, 2025, against a $135.5 million accumulated deficit.